In this article (Cancer Res 2006;66(7):3802–12) published in the April 1, 2006 issue of Cancer Research (1), an error was made in Fig. 5B. The same image was used to represent pMAPK expression in control samples from both MiaPaCa-2 and L3.6pl tumor xenografts and the image intensity/contrast was significantly altered. The panels in question are shown below:

The authors have corrected the figure and regret their error. The corrected Fig. 5B appears below:

Corrections for several articles published in AACR journals containing similar errors have been published. The original articles and their corrections are:

  • Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K, Jr., Huang P, Abbruzzese JL, McConkey DJ. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005;65:11658–66. doi:10.1158/0008-5472.CAN-05-2370.

  • Correction In: Cancer Res 2009;69:1695. Published OnlineFirst February 10, 2009. doi: 10.1158/0008-5472.CAN-69-4-COR1.

  • Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243–53.

  • Correction In: Mol Cancer Ther 2009;8:3388–9. Published OnlineFirst December 1, 2009. doi: 10.1158/1535-7163.MCT-09-1072.

  • Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3:59–70.

  • Correction In: Mol Cancer Ther 2009;8:479. Published OnlineFirst February 3, 2009. doi: 10.1158/1535-7163.MCT-08-2-COR1.

  • Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006;5:3032–41. doi: 10.1158/1535-7163.MCT-05-0474.

  • Correction In: Mol Cancer Ther 2009;8:480. Published OnlineFirst February 3, 2009. doi: 10.1158/1535-7163.MCT-08-2-COR2.

The errors in the aforementioned articles were caused in large part by inadequate oversight of data management. In an effort to prevent such errors from occurring in the future, the PI (DJM) has implemented a new data management policy that is designed to limit or eliminate errors in future publications, and would be happy to provide it to anyone interested upon request ( The authors note that the conclusions and interpretation of the data in these articles are unaltered by the errors that are now corrected.

Transforming growth factor α expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines
Cancer Res
doi: 10.1158/0008-5472.CAN-05-3753